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doi:10.1016/j.pedneo.2011.08.009Henoch-Scho¨nlein purpura (HSP) or hepatitis C virus (HCV) infection was reported in associa-
tion with malignancies. However, HSP and HCV infection rarely present in pediatric patients
with non-Hodgkin’s lymphoma. We describe an 8-year-old girl with Stage-IV diffuse large B-cell
lymphoma who presented with HSP and elevated HCV antibody titer at diagnosis and at
relapse. After treatment, purpura disappeared and HCV antibody titer returned to normal
range. There was no recurrence of HSP or elevated HCV antibody during a follow-up of 2 years.
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Henoch-Scho¨nlein purpura (HSP) is a systemic vasculitis
affecting small vessels with immunoglobulin A (IgA)-domi-
nant immune deposits; characteristic involvement with
skin, gastrointestinal tract and glomeruli; and association
with arthritis or arthralgia.1 HSP is more frequent in children
than adults. Vasculitis has been described in association
with neoplasm.2 However, HSP associated with malignancyed by Elsevier Taiwan LLC. All rights reserved.
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children.3 The role of hepatitis C virus (HCV) infection in
non-Hodgkin’s lymphoma (NHL) is still controversial.4e6
Herein, we report an 8-year-old girl with Stage-IV diffuse
large B-cell lymphoma (DLBCL) who presented with HSP and
elevated HCV antibody titer at diagnosis and at relapse. She
has been in continuous second remission for 24 months.2. Case Report
An 8-year-old naturally healthy girl was referred to our
pediatric department for intermittent epistaxis for 1 month.
Also, she had had multiple palpable purpura on both lower
legs off and on for 6 months. Fever, cough, and rhinorrhea
had developed for the preceding 2 days. Physical examina-
tion showed hepatosplenomegaly and nasal mass with active
bleeding. Complete blood counts revealed hemoglobin
109 g/L, mean corpuscular volume 82.4 fL, white blood cell
count 8.1 109/L, normal differential counts, and platelets
187 109/L. Prothrombin time, activated partial thrombo-
plastin time, and bleeding time were within normal range.
The urine analysis was normal. Brain computed tomography
scan showed a tumor mass (2.5 cm 4 cm 3.5 cm) in the
nasopharynx. Nasopharyngeal biopsy confirmed DLBCL,
which showed a panel of immunoreactivity, positive for
CD79a and CD20 and negative for CD56, TdT, or CD45RO.
Bone marrow biopsy revealed tumor cell involvement.
Cerebrospinal fluid analysis and cytospin were normal.
Tc99mwhole-body bone scan showed increased uptake in the
skull base, probably reflecting local tumor invasion. Serology
studies showed serum lactate dehydrogenase: 397 U/L,
aspartate transaminase: 43 U/L, alanine transaminase:Figure 1 Immunofluorescent stain of skin biopsy revealed IgA,
superficial dermis. IgG was negative (not shown). The findings were
IgAZ immunoglobulin A; IgMZ immunoglobulin M.9 U/L, blood urea nitrogen: 6 mg/dL, creatinine: 0.3 mg/dL,
and IgA: 355 mg/dL (normal range: 45e236 mg/dL). HCV
antibody was 7.77 (reference range was less than 1.00),
whereas HCV-RNA titer was negative (less than 10 IU/mL).
This patient was considered Stage-IV DLBCL according to
the St. Jude Children’s Research Hospital Staging System.7
She was treated with Taiwan Pediatric Oncology Group 98
B-NHL protocol, which is based on the BFM-90 protocol,8
with minor modification. Risk group was classified as
BFM-R3. Purpura disappeared soon after treatment was
initiated. After cytoreductive prephase, two more courses
of chemotherapy (AA, BB) were used. Bone marrow biopsy
revealed remission, whereas nasopharyngeal biopsy still
displayed residual tumor. Because of unsatisfactory
response, CC course was followed. Then, nasopharyngeal
biopsy disclosed no residual tumor. Consecutive treatment
with AA, BB, and CC courses proceeded. Post-treatment
evaluation revealed free of lymphoma.
However, 4 months after completion of treatment,
fever, and purpura on both of the patient’s lower legs
recurred. Serum IgA was 231 mg/dL. C3, C4, and antinu-
clear factor titer were within normal limits. HCV antibody
titer was 1.45 and HCV-RNA titer was negative. Lactate
dehydrogenase titer was 170 U/L. Skin biopsy of purpura on
the right dorsal foot revealed leukocytoclastic vasculitis
and tissue immunofluorescence demonstrated IgA, IgM, C3,
and fibrinogen depositions on blood vessels of the superfi-
cial dermis while not for IgG (Figure 1). Brain computed
tomography scan showed thickening of the bilateral post-
erosuperior wall of nasopharynx. Nasopharyngeal biopsy
revealed relapse of DLBCL, whereas bone marrow biopsy
showed still in remission. Marrow donor search failed to
find an HLA-match donor. R-CHOP regimen9 (rituximabIgM, C3, and fibrinogen depositions on blood vessels of the
consistent with vasculitis, including Henoch-Scho¨nlein purpura.
HSP and elevated HCV antibody in DLBCL 351375 mg/m2/d D1, cyclophosphamide 750 mg/m2/d D1, epi-
doxorubicin 50 mg/m2/d D1, vincristine 1.4 mg/m2/d D1,
prednisolone 100 mg/m2/d D1e5) was given for six courses.
Second remission was achieved. The serum IgA was 15 mg/
dL, and HCV antibody titer was 0.79 in the latest follow-up.
The patient has been in second remission for 2 years.3. Discussion
In our patient, elevated serum IgA level was noted at
diagnosis. Although serum IgA level was not checked during
the first remission period, it was still within high normal
limit at relapse. However, serum IgA declined to very low
level after achievement of second remission. Purpura dis-
appeared soon after treatment was started at diagnosis and
relapse. Because the diagnosis of HSP is usually clinical,
skin biopsy is not routinely performed in most patients.
Leukocytoclastic vasculitis with IgA deposition may be
found in HSP, acute infantile hemorrhagic edema, infective
endocarditis, and erythema elevatum dinutum.10 The
typical clinical manifestations of HSP involving renal and
gastrointestinal tract disease and arthritis were not
observed in our patient. The initial diagnosis of HSP was
later confirmed at recurrence by skin biopsy, which dis-
closed leukocytoclastic vasculitis with immune deposits.
We considered that the skin finding might be associated
with the patient’s underlying lymphoma. The frequency of
recurrent HSP was reported to be approximately 35% in the
literature.11 There was no known report for recurrent HSP-
associated malignancies in pediatric patients.
Vasculitis has been described as a paraneoplastic
syndrome, and the frequency of associated malignancy in
vasculitis is about 2.5e5%.2 With regard to lymphomas,
the vasculitis seems more common in association with
NHLs.12 The course of paraneoplastic vasculitis-associated
lymphoma is usually cutaneous localized urticarial or
leukocytoclastic type, whereas there is less systemic
involvement with fulminant type.12e14 HSP coexisting with
malignancy has rarely been reported and tended to occur in
older male adults. Hence, elderly patients with HSP lacking
triggers should be evaluated for underlying malignancy.3
Although hematologic malignancies were more common
than solid tumors in cutaneous vasculitis, solid tumors were
more frequent in association with HSP.3 Abnormal function
of lymphocytes was found in patients with active HSP.15
Excessive IgA antibody produced by hyper-reactive B-
lymphocytes could contribute to an immune complex
reaction to antigens. Hyperviscous state in patients with
malignancy may increase the contact time of immune
complexes with endothelium and enhance deposition to
blood vessels and lead to the development of HSP.16 The
pathophysiology of paraneoplastic vasculitis remains indis-
tinct. Other potential mechanisms of paraneoplastic
vasculitis have been proposed, including decreased clear-
ance of immune complex, similarities between tumor and
endothelial cell antigens, treatment of cancer altered cell
surface antigens, abnormal formation of proinflammatory
cytokines by neoplasm, and isotype switch from IgM to IgA
caused by dysregulated lymphocytes.3,17e20
Previous studies revealed onset of HSP occurring within 1
year before or after the diagnosis of malignancy.3 In ourpatient, HSP preceded the diagnosis of DLBCL by 6 months.
HSP disappeared soon after treatment of the DLBCL and
recurred concomitantly with the recurrence of DLBCL 4
months after complete treatment. Hutson and Hoffman21
suggested that vasculitis resistant to traditional therapy
should be reviewed for underlying malignancy, and effec-
tive therapy of malignancies might improve vasculitis. The
recurrence of vasculitis proclaiming tumor recurrence or
progression indicates vasculitis to be a real paraneoplastic
syndrome. Therefore, one should be alert to tumor recur-
rence when vasculitis develops.
HCV has been demonstrated to have lymphotrophism, in
addition to its known hepatotrophism, as HCV-RNA can be
found in the peripheral blood mononuclear cells of patients
with chronic HCV infection.22 Previous studies revealed that
the prevalence of HCV infection in patients with NHL had
geographical variations.4e6 In a recent prospective study by
Vallat et al,23 the frequencies of clonal B-lymphocytes
detected in blood and liver of patients with chronic HCV
infection were 26% and 32%, respectively, without overt
B-cell malignancy. These clones were frequently associated
with Type II cryoglobulins. In 25% of patients with B-cell
clonality in both blood and liver, definite B-cell malignan-
cies may develop. The mechanism of malignant trans-
formation of clonal B-cells in patients with HCV infection
remains unclear. HCV antibody may be negative in immu-
nocompromised patients with HCV infection, and HCV-RNA
testing may be more reliable.24 The elevation of HCV
antibody and negativity of HCV RNA titer in our patient was
also observed in other studies.4,5 Our patient had never
received blood transfusion or intravenous drug. Interest-
ingly, HCV antibody decreased after treatment for DLBCL
and was normal in the latest follow-up. Thus, we consider
that our patient was not infected with HCV actually. The
transient elevation of HCV antibody may result from
deranged immune response of B-lymphocytes, which needs
further research.
In conclusion, this report suggests that patients with
recurrent vasculitis should be evaluated for possible
underlying malignancy. Besides, patients who develop
vasculitis and have a history of cancer should also be
investigated for relapse.
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